Share on StockTwits
 

Shares of Smith & Nephew plc (LON:SN) have earned an average recommendation of “Hold” from the twenty analysts that are presently covering the company, Stock Ratings News reports. Three research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is GBX 884.38 ($14.71).

Several analysts have recently commented on the stock. Analysts at Berenberg Bank reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Friday, February 14th. They now have a GBX 920 ($15.30) price target on the stock. Separately, analysts at Deutsche Bank upgraded shares of Smith & Nephew plc to a “buy” rating in a research note on Wednesday, February 12th. They now have a GBX 1,125 ($18.71) price target on the stock, up previously from GBX 650 ($10.81). Finally, analysts at Beaufort Securities upgraded shares of Smith & Nephew plc to a “buy” rating in a research note on Friday, February 7th.

Smith & Nephew plc (LON:SN) traded down 0.57% on Tuesday, hitting GBX 954.50. The stock had a trading volume of 667,025 shares. Smith & Nephew plc has a one year low of GBX 693.50 and a one year high of GBX 964.0001. The stock has a 50-day moving average of GBX 899.0 and a 200-day moving average of GBX 825.0. The company’s market cap is £8.543 billion.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.